Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to $1.8 million.

  • Altimmune's Non-Current Assets fell 12.97% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 12.97%. This contributed to the annual value of $2.1 million for FY2024, which is 102.37% up from last year.
  • Per Altimmune's latest filing, its Non-Current Assets stood at $1.8 million for Q3 2025, which was down 4.98% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Non-Current Assets peaked at $19.1 million during Q1 2021, and registered a low of $843,000 during Q1 2024.
  • Over the past 3 years, Altimmune's median Non-Current Assets value was $2.1 million (recorded in 2024), while the average stood at $5.0 million.
  • Per our database at Business Quant, Altimmune's Non-Current Assets tumbled by 93.97% in 2024 and then soared by 137.37% in 2025.
  • Quarterly analysis of 5 years shows Altimmune's Non-Current Assets stood at $14.7 million in 2021, then decreased by 4.23% to $14.1 million in 2022, then tumbled by 92.82% to $1.0 million in 2023, then surged by 102.37% to $2.1 million in 2024, then fell by 12.97% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.9 million for Q2 2025, and $2.0 million during Q1 2025.